Business Context and Reporting Period
This Form 8-K Current Report was filed by Armata Pharmaceuticals, Inc. (ARMP) on July 22, 2024. The filing addresses Item 5.02 regarding the amendment of an employment agreement for a senior officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: Dr. Mina Pastagia's base salary is confirmed at $456,800 annually.
- Bonus Opportunity: A target annual bonus of 50% of base salary is established commencing with the 2024 fiscal year.
- Equity Grants: Eligibility for additional equity grants commences in 2025, with a current intent for a grant date fair value of $300,000.
- Severance: In the event of termination without "cause" or resignation for "good reason," the executive is entitled to 12 months of base salary continuation.
Material Changes
The primary material change is the formal amendment of Dr. Pastagia's employment agreement to reflect her role as Chief Medical Officer (serving since January 1, 2023) and to codify her compensation structure, including the new bonus target and future equity grant eligibility.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The only contingency noted is the severance provision triggered by specific termination conditions defined in the agreement.
Investor Verification Checklist
- Verify the full text of the Employment Agreement and Amendment (Exhibits 10.1 and 10.2) for detailed definitions of "cause" and "good reason."
- Confirm the impact of the new bonus and equity grant structure on the company's future cash burn and dilution.
- Review the company's 2024 fiscal year performance to assess the likelihood of the target bonus being achieved.